Results 41 to 50 of about 18,928 (205)

Stroke following percutaneous coronary intervention : type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12 [PDF]

, 2016
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015.
Berry, Colin, British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research, Buchan, Iain, de Belder, Mark A, Keavney, Bernard, Kontopantelis, Evangelos, Kwok, Chun Shing, Ludman, Peter F, Mamas, Mamas A, Myint, Phyo K, Nolan, Jim, Zaman, Azfar   +11 more
core   +1 more source

Simultaneous Determination of Prasugrel and Aspirin by Second Order and Ratio First Order Derivative Ultraviolet Spectrophotometry

Journal of Spectroscopy, 2013
Two simple, accurate, and precise UV derivative spectrophotometric methods for the simultaneous determination of Prasugrel and Aspirin in synthetic mixture form have been developed. The first method involves measurement of second order derivative spectra
Shahabuddin N. Alvi, Mehul N. Patel, Prakash B. Kathiriya, Bhavna A. Patel, Shraddha J. Parmar   +4 more
doaj   +1 more source

Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]

, 2018
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA, Robert H., Saad, MD, Hassan, Smith, MD, Michelle, Tjoumakaris, MD, Stavropoula, Zarzour, MD, Hekmat   +9 more
core   +2 more sources

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis

BMC Cardiovascular Disorders, 2020
Background This meta-analysis aimed to compare the effects of prasugrel and ticagrelor on high (HTPR) and low on-treatment platelet reactivity (LTPR) in patients with acute coronary syndrome (ACS).
Mingxiang Wen, Yaqi Li, Xiang Qu, Yanyan Zhu, Lingfang Tian, Zhongqin Shen, Xiulin Yang, Xianqing Shi   +7 more
doaj   +1 more source

Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications.

PLoS ONE, 2023
Background and purposeProphylactic prasugrel for endovascular treatment of intracranial aneurysms has been introduced and increased, but HTPR (high on-treatment platelet reactivity) or LTPR (low on-treatment platelet reactivity) of prasugrel is not ...
Noah Hong, Seung Bin Kim, Hee-Jin Yang, Young-Je Son   +3 more
doaj   +1 more source

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Management of patients with non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS) is based on 2020 European Society of Cardiology guidelines, which recommend the preferential use of prasugrel over ticagrelor. Because the selection of the
Mustafa Yildirim, Matthias Mueller‐Hennessen, Barbara Ruth Milles, Moritz Biener, Hauke Hund, Norbert Frey, Evangelos Giannitsis, Christian Salbach   +7 more
doaj   +1 more source

Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. [PDF]

, 2018
OBJECTIVES: Prasugrel and ticagrelor both reduce ischaemic endpoints in high-risk acute coronary syndromes, compared with clopidogrel. However, comparative outcomes of these two newer drugs in the context of primary percutaneous coronary intervention ...
Baumbach, A, British Cardiovascular Intervention Society and the National Ins,, Byrne, J, Curzen, N, de Belder, MA, Hildick-Smith, DJR, Kinnaird, T, Ludman, P, Mamas, MA, Olier, I, Rashid, M, Sirker, A   +11 more
core   +1 more source

Eversion endarterectomy under full prasugrel treatment

SAGE Open Medical Case Reports, 2017
The third-generation thienopyridine prasugrel has much stronger antiplatelet effect compared to other current antiplatelet inhibitors and exhibits practically zero resistance in healthy people.
Thomas Kotsis, Panagitsa Christoforou, Nikolaos Asaloumidis, Erifyli Argyra   +3 more
doaj   +1 more source

PrasugRel versus adjusted high-dose clopidogrel in patients with high on- clopidogrel platelet reactivity: the PECS-HPR randomized, multicenter study [PDF]

, 2015
background: Repeated loading doses (LD) of clopidogrel were shown to effectively overcome high on-clopidogrel platelet reactivity (HPR); however, comparison to potent P2Y12-inhibitors is lacking.
Aradi, Dániel
core   +1 more source